Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.

Authors :: Roque DM
Siegel ER
Buza N
Bellone S
Silasi DA
Huang GS
Andikyan V
Clark M
Azodi M
Schwartz PE
Rao GG
Reader JC
Hui P
Tymon-Rosario JR
Harold J
Mauricio D
Zeybek B
Menderes G
Altwerger G
Ratner E
Santin AD
Source :: British journal of cancer [Br J Cancer] 2024 Apr; Vol. 130 (6), pp. 1073.
Publication Year :: 2024

Full Text Access

Tools